Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
427

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of Life Lost in Incidental Prostate Cancer.

The Prostate·2026
Same author

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026
Same author

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Mediterranean journal of rheumatology·2026
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

Quantitative assessment of interstitial lung disease in rheumatoid arthritis.

Reumatologia clinica·2026

Related Experiment Video

Updated: Jan 6, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.

Eleonora Celletti1, Myriam Di Penta2, Alarico Ariani3

  • 1Rheumatology Unit, Clinica Medica Institute, Ospedale "SS. Annunziata" di Chieti/Università "G. d'Annunzio", Chieti, Italy.

Rheumatology and Therapy
|December 4, 2025
PubMed
Summary
This summary is machine-generated.

Filgotinib (FIL) shows effectiveness and a high drug retention rate in real-world rheumatoid arthritis (RA) patients. This study confirms FIL

Keywords:
Drug retention rateEffectivenessEfficacyFilgotinibJAK inhibitorRheumatoid arthritisSafetybDMARDcsDMARDtsDMARD

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

770
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

948

Related Experiment Videos

Last Updated: Jan 6, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

770
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

948

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Research

Background:

  • Randomized controlled trials (RCTs) established filgotinib (FIL) efficacy and safety in rheumatoid arthritis (RA).
  • Limited real-world data exists on FIL's effectiveness, persistence, tolerability, and safety in clinical practice.
  • This study addresses the need for real-world evidence on FIL in RA management.

Purpose of the Study:

  • To assess the real-world effectiveness of filgotinib (FIL) in patients with rheumatoid arthritis (RA).
  • To evaluate the drug retention rate (DRR) of FIL in a diverse RA patient cohort.
  • To identify factors influencing FIL persistence in routine clinical settings.

Main Methods:

  • Multicenter retrospective cohort study involving 204 RA patients across 27 Italian rheumatology centers.
  • Kaplan-Meier method used to estimate drug retention rate (DRR).
  • Multivariate Cox regression analyzed factors affecting drug survival; DAS28-CRP assessed at baseline, 6, and 12 months.

Main Results:

  • High drug retention rates observed: 90.2% at 6 months, 75.1% at 12 months, and 64.7% at 18 months.
  • Lower DRR associated with later lines of treatment and rheumatoid factor positivity.
  • Significant effectiveness shown by DAS28-CRP response: 36.1% achieved remission at 6 months, increasing to 50.0% at 12 months.

Conclusions:

  • Real-world data confirms filgotinib (FIL) is effective for rheumatoid arthritis (RA) management.
  • FIL demonstrates a favorable drug retention rate and good Disease Activity Score 28-CRP (DAS28-CRP) response in clinical practice.
  • This study supports FIL's utility as a treatment option for RA patients outside of controlled trial settings.